



On the Clinical Pharmacology of Reactive Oxygen
Species
Citation for published version (APA):
Casas, A., Nogales, C., Mucke, H. A. M., Petraina, A., Cuadrado, A., Rojo, A., Ghezzi, P., Jaquet, V.,
Augsburger, F., Dufrasne, F., Soubhye, J., Deshwal, S., Di Sante, M., Kaludercic, N., Di Lisa, F., &
Schmidt, H. H. H. W. (2020). On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological
Reviews, 72(4), 801-828. https://doi.org/10.1124/pr.120.019422





Publisher's PDF, also known as Version of record
Document license:
Unspecified
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Feb. 2021
1521-0081/72/4/801–828$35.00 https://doi.org/10.1124/pr.120.019422
PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:801–828, October 2020
Copyright © 2020 by The Author(s)
This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.
ASSOCIATE EDITOR: RHIAN M. TOUYZ
On the Clinical Pharmacology of Reactive Oxygen
Species
Ana I. Casas, Cristian Nogales, Hermann A. M. Mucke, Alexandra Petraina, Antonio Cuadrado, Ana I. Rojo, Pietro Ghezzi, Vincent Jaquet,
Fiona Augsburger, Francois Dufrasne, Jalal Soubhye, Soni Deshwal, Moises Di Sante, Nina Kaludercic, Fabio Di Lisa,
and Harald H. H. W. Schmidt
Department of Pharmacology and Personalized Medicine, Maastricht University, School of Mental Health and Neuroscience (MHeNS),
Maastricht, The Netherlands (A.I.C., C.N., A.P., H.H.H.W.S.); H. M. Pharma Consultancy, Wien, Austria (H.A.M.M.); Centro de
Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Instituto de Investigaciones Biomédicas
“Alberto Sols” UAM-CSIC, Instituto de Investigación Sanitaria La Paz (IdiPaz), Department of Biochemistry, Faculty of Medicine,
Autonomous University of Madrid, Madrid, Spain (A.C., A.I.R.); Brighton and Sussex Medical School, Falmer, United Kingdom (P.G.);
Department of Pathology and Immunology, Medical School, University of Geneva, Geneva, Switzerland (V.J., F.A.); Microbiology, Bioorganic
and Macromolecular Chemistry, RD3, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), Bruxelles, Belgium (F.D., J.S.); and Department
of Biomedical Sciences (S.D., M.D.S., F.D.L.) and CNR Neuroscience Institute (N.K., F.D.L.), University of Padova, Padova, Italy
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 802
Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 802
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 802
II. ROS Revisited: From Oxidative Stress and Redox Biology to Redox Medicine . . . . . . . . . . . . . . . . 804
III. ROS Generators and Toxifiers in Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805
A. Focus on Oxidases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805
1. NADPH Oxidase. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805
2. Nitric Oxide Synthases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 807
3. Xanthine Oxidase. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808
4. Monoamine Oxidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808
B. Focus on Toxifiers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809
1. Myeloperoxidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809
IV. Pharmacological Modulation of ROS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809
A. Inhibition of ROS Formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809
1. NADPH Oxidase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809
a. Limitations of NOX inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 811
2. NO Synthase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812
3. Xanthine Oxidoreductase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 813
4. Monoamine Oxidase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 814
B. Inhibition of ROS Toxification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815
1. Myeloperoxidase Inhibitors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815
a. Reversible inhibitors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815
b. Irreversible inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815
V. Targeting ROS Beyond Oxidases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 816
A. Direct Antioxidants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 816
B. Indirect Antioxidants: NRF2 Activators. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818
C. Functional Repair of ROS-Induced Damage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819
1. sGC Activators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819
2. sGC Stimulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 820
Address correspondence to: Dr. Ana I. Casas, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.
E-mail: a.casasguijarro@maastrichtuniversity.nl; or Harald H. H. W. Schmidt, Maastricht University, Universiteitssingel 50, 6229 ER
Maastricht, The Netherlands. E-mail: h.schmidt@maastrichtuniversity.nl
This study was supported by the European Research Council Advanced Investigator Grant/RadMed [Grant 294683], Proof-of-Concept
Grant/SAVEBRAIN [Grant 737586], and H2020 Project REPO-TRIAL [Grant 777111] (to H.H.H.W.S.) and short-term scientific missions by










VI. Biomarkers of ROS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821
A. Xanthine Oxidase and Myeloperoxidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821
B. ROS-Dependent Protein Modification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821
C. ROS-Dependent DNA/RNA Modification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821
VII. Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822
Abstract——Reactive oxygen species (ROS) have
been correlated with almost every human disease. Yet
clinical exploitation of these hypotheses by pharmaco-
logical modulation of ROS has been scarce to non-
existent. Are ROS, thus, irrelevant for disease? No.
One key misconception in the ROS field has been its
consideration as a rather detrimental metabolic by-
product of cell metabolism, and thus, any approach
eliminating ROS to a certain tolerable level would be
beneficial. We now know, instead, that ROS at every
concentration, low or high, can serve many essential
signaling and metabolic functions. This likely explains
why systemic, nonspecific antioxidants have failed in
the clinic, often with neutral and sometimes even
detrimental outcomes. Recently, drug development
has focused, instead, on identifying and selectively
modulating ROS enzymatic sources that in a given
constellation cause disease while leaving ROS
physiologic signaling and metabolic functions intact.
As sources, the family of NADPH oxidases stands out
as the only enzyme family solely dedicated to ROS
formation. Selectively targeting disease-relevant ROS-
related proteins is already quite advanced, as evidenced
by several phase II/III clinical trials and the first
drugs having passed registration. The ROS field
is expanding by including target enzymes and
maturing to resemble more and more modern, big
data–enhanced drug discovery and development,
including network pharmacology. By defining a disease
based on a distinct mechanism, in this case ROS
dysregulation, and not by a symptom or phenotype
anymore, ROS pharmacology is leaping forward from
aclinical underperformer to aproof of conceptwithin the
new era of mechanism-based precision medicine.
Significance Statement——Despite being correlated
to almost every human disease, nearly no ROS modu-
lator has been translated to the clinics yet. Here, we
move far beyond the old-fashioned misconception
of ROS as detrimental metabolic by-products and
suggest 1) novel pharmacological targeting focused
on selective modulation of ROS enzymatic sources, 2)
mechanism-based redefinition of diseases, and 3)
network pharmacology within the ROS field, altogether
toward the new era of ROS pharmacology in precision
medicine.
I. Introduction
For decades, the oxidative stress theory has placed
ROS as the basis of numerous disease states (Ghezzi
et al., 2017). Consequently, antioxidants have been
broadly tested as therapeutic agents for neurodegen-
erative diseases (Schmidt et al., 2015), cancer (Nezis
and Stenmark, 2012), brain ischemia (Lees et al.,
2006), and endothelial dysfunction (Ashor et al.,
2014), to name a few. So far, hardly any of them have
reached the efficacy and or safety criteria sufficient
for drug approval. There is only one approved antiox-
idant drug, edaravone, to treat a small subset (Abe
et al., 2017) of patients with amyotrophic lateral
sclerosis (Hardiman and van den Berg, 2017). From
a clinical pharmacological perspective, the questions
arise as to whether the oxidative stress theory is
wrong, whether ROS are a therapeutic target at all,
and whether the wrong diseases or wrong approaches
have been chosen.
One fundamental theory of ROS biology that intro-
duced a considerable bias for redox medicine has been
the concept of whole-cell redox balance or homeostasis
(Sies, 2019). Moreover, the notion that ROS are dan-
gerous metabolic by-products to be controlled to a cer-
tain tolerable level to prevent oxidative stress remains
as controversial theory. In fact, the existence of antiox-
idant enzymes such as superoxide dismutase (McCord
and Fridovich, 1988) could be viewed in support of this
bias. Many other second messengers, however, are also
controlled by both synthesis (e.g., cyclases, kinases) and
degradation (e.g., phosphodiesterases, phosphatases).
This would argue both against the notion of ROS being
primarily detrimental and against an ROS-specific
cellular mechanism to ensure local steady-state levels
of a signalingmolecule. If ROS formation is dysregulated
and triggers disease, this may happen only in a certain
cellular compartment, whereas many other simulta-
neous ROS signaling events in different compartments
may still be required for essential physiologic processes,
ABBREVIATIONS: ALS, amyotrophic lateral sclerosis; ClTyr, chloro-tyrosine; CVD, cardiovascular disease; DMF, dimethyl fumarate;
DUOX, dual oxidase; H4Bip, tetrahydrobiopterin; HFpEF, heart failure with preserved ejection fraction; H2O2, hydrogen peroxide; IFN,
interferon; IL, interleukin; KEAP1, Kelch-like ECH-associated protein 1; MAO, monoamine oxidase; MPO, myeloperoxidase; MS, multiple
sclerosis; NO, nitric oxide; NO2Tyr, 3-nitrotyrosine; NOS, NO synthases; NOSTRA, No Synthase in Traumatic Brain Injury; NOX, NADPH
oxidase; NRF2, nuclear factor (erythroid-derived 2)-like 2; O2
•, superoxide; 8-oxodG, 8-oxo-29-deoxyguanosine; PKG, protein kinase G; PPI,
protein-protein interaction; ROCG, ROS-cGMP signaling network; ROS, reactive oxygen species; sGC, soluble guanylate cyclase; UA,
uric acid; XDH, xanthine dehydrogenase; XO, Xanthine oxidase; XOR, xanthine oxidoreductase.
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such as cell differentiation and proliferation, im-
mune response, vascular tone, and hormone synthesis
(Altenhöfer et al., 2015). This would argue against
a whole-cell redox status. Moreover, these latter
physiologic roles of ROS can occur at both high and
low concentrations, demonstrating a strictly quantita-
tive criteria for ROS being physiologic or pathologic, and
this may explain the recurrent failures in translating
broadly acting antioxidants for clinical application
(Steinhubl, 2008). Finally, disease-relevant ROS dysre-
gulation may include the following: 1) the induction of
ROS-forming enzymes and local overproduction of ROS;
2) translocation of ROS-forming enzymes to cellular sites
where, physiologically, there is no ROS formation; 3)
unphysiological ROS formation interfering with ROS-
sensitive pathways; or 4) changes in the ROS formed,
e.g., superoxide or peroxynitrite instead of hydrogen
peroxide or nitric oxide (Dröge, 2002; Casas et al., 2015;
Dao et al., 2015).
The novel and more clinically promising pharmaco-
logical approach to ROS reviewed here suggests selec-
tively inhibiting only the disease-relevant ROS sources
and leaving all others intact. To achieve this, disease
relevance and target validation have to go beyond the
concept of “small amounts of ROS beneficial or toler-
able, large amounts detrimental” and no longer use
terms such as “redox balance,” “redox gradient,” or
“oxidative stress”; instead, the identification of a specific
enzyme’s dysregulation as a causal disease mechanism
is required (Ghezzi et al., 2017). Also, cases of secondary
ROS formation as a by-product of many inflammatory
reactions (e.g., NOX2 or NOS2) are most likely an
epiphenomenon not suited as a therapeutic target. We
thus strictly limit this review to clinical validations at
the level of at least a phase II clinical trial or higher.
This excludes, for now, some targets commonly consid-
ered in basic and preclinical research, such as 1)
mitochondria and ROS-induced ROS release, which, in
our view, may occur but are currently not realistic to be
safely targeted pharmacologically in humans; or 2)
other ROS sources for which hitherto no disease or
therapeutic relevance has been shown.
Therefore, the ROS-forming andmetabolizing enzymes
considered for this review include NADPH oxidase
(NOX) (Schramm et al., 2012; Rousset et al., 2015;
Warren et al., 2017), NO synthase (NOS) (Li and
Pagano, 2017), xanthine oxidoreductase (XOR) (Berry
andHare, 2004), monoamine oxidase (MAO) (Bortolato
et al., 2008), andmyeloperoxidase (MPO) (Malle et al.,
2007). Additionally, we include proteins that are not
generally considered by the ROS field. However, we
view them as mechanistically related and therapeu-
tically relevant (in particular, targets of ROS) if they
are disease-relevant and amenable to pharmacologi-
cal modulation, i.e., nuclear factor (erythroid-derived
2)-like 2 (NRF2) and its activators (Dao et al., 2015;
Cuadrado et al., 2019) and the nitric oxide synthase
(NOS)-soluble guanylate cyclase (sGC) signaling pair
(Evgenov et al., 2006). Drugs targeting sGC (Sandner
et al., 2019) do not modulate ROS formation directly but
correct functionalROS-dependent dysregulation (Melichar
et al., 2004).
Maturing the ROS field concerning successful drug
discovery is confronted, however, with an even more
significant challenge that the entire pharmaceutical
industry and biomedicine field in general faces. Even for
several drugs that are on the market, population-based
studies fail to show patient-relevant benefits (Lee et al.,
2012; Nosengo, 2016). Moreover, research covering drug
approvals since the 1970s suggests that only a limited
number of new drugs provide real advances over
existing drugs; most studies put the proportion of real
innovation at under 15% (Ebrahim, 2001). One of the
factors contributing to this innovation roadblock is
a conceptual knowledge gap applied to the whole field
ofmedicine and our current definitions of diseases.Most
diseases are defined based on a dominant symptom—
indeed, mostly in one organ.However, they are often not
defined based on a causal molecular mechanism, which
for most common diseases, is not known. A drug,
however, can only be effectively developed and applied
in a precise manner if themolecular disease mechanism
is known (Caldera et al., 2019; Choobdar et al., 2019).
As we are moving to molecular redefinitions of
disease (Aguirre-Plans et al., 2018), we realize that
common diseases are not defined by single causal
proteins, unlike in highly penetrant monogenic dis-
eases, but rather by a dysregulated signaling network
as part of the cellular interactome (Sharma et al., 2015).
Indeed, proteins associated with specific diseases are
not randomly spread but tend to interact, forming
connected subgraphs, i.e., disease modules (Menche
et al., 2015). A given ROS source or ROS target may
be part of one such disease module but not another. In
fact, different modules may cause different or similar
symptoms (phenotypes) (Ghiassian et al., 2016). More-
over, there are several ways of defining disease models.
The Disease Module Identification DREAM Challenge
was recently launched as an open competition to assess
diverse identification methods (Choobdar et al., 2019).
Although all models in the ROS field give almost
identical results, we selected the first-neighbor ap-
proach obtained from validated protein-protein inter-
actions (PPIs) within the experimentally assessed
interactome (Zhang and Itan, 2019). These disease
models were further pruned according to the subnet-
work participation degree to correct for hub node
proteins. Then, identification of disease models is,
therefore, occurring because of the high number of
interactions in the whole network. Thus, we present
here the first draft of a network pharmacology approach
to redox medicine based on clinically validated thera-
peutic ROS targets (seed genes) and associated con-
struction of disease modules (Fig. 1).
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This “ROSome” currently shows 10 distinct PPI
modules. One module overlaps with cGMP signaling
(ROS-cGMP, i.e., ROCG module). Moreover, modules
may interact not only through PPI but also functionally
through metabolites, as shown for the ROCG and the
NOX4 module (Casas et al., 2019a), reducing the
ROSome to nine functional modules. Therefore, we
show here that different ROS sources belong to non-
connected modules and, thus, probably different dis-
eases. Hence, we need to identify mechanism-related
targets that will only be associated with some ROS-
related disease phenotypes presenting specific ROS
source-disease couples and no longer considering ROS
as a general disease mechanism. Since all seed proteins
are disease-relevant, these functional modules will be
starting points for ROS-related target selection, diag-
nostics, and therapeutic prioritization as part of new
mechanistic disease definitions. Thus, what we cur-
rently name a disease would be annotated as a pheno-
type or symptom of this “mechanotype” (Schmidt et al.,
2018). Hence, we propose 1) novel pharmacological
targeting focused on selective modulation of ROS
enzymatic sources, 2) mechanism-based redefinition of
diseases, and 3) implementation of network pharma-
cology approaches as the future of the ROS field in the
new era of precision medicine.
II. ROS Revisited: From Oxidative Stress and
Redox Biology to Redox Medicine
Based on the above, both the terms disease and redox
medicine need to be renewed. One common bias has
been a focus on the roles of ROS in disease rather than
in physiology, thereby overlooking or neglecting many
Fig. 1. A mechanotype approach to ROS-related diseases. Red shows validated ROS-related disease targets and their first neighbors (blue). A
participation degree score was calculated for each protein by the ratio of total protein-protein interactions in the subnetwork to the total protein-
protein interaction in the interactome. A cutoff of 0.25 was chosen for the participation degree score to filter non–cluster-relevant highly promiscuous
proteins. These data suggest that ROS pathophysiology is split up into at least 10 distinct mechanotypes, which will become mechanistic disease
definitions. Once metabolites are included, possible new module connections may appear, such as NOX4 linking into NOS1 signaling (Casas et al.,
2019a).
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of their nonpathologic roles (Ghezzi et al., 2017). Phys-
iologic ROS sources are expressed in different cell
structures, i.e., mitochondria, peroxisomes, endoplasmic
reticulum, lysosomes, and plasma membrane (Di Meo
et al., 2016). Based on their distribution and colocaliza-
tion, the activation of different ROS sources will result in
differential subcellular superoxide (O2
•), hydrogen perox-
ide (H2O2), hydroxyl, or [by interaction with nitric oxide
(NO) or nitrite] peroxynitrite formation.
Physiologic ROS production is involved in several
essential signaling functions regulating cell growth,
necrosis, apoptosis, proliferation, and survival (Zuo
et al., 2015); immune system functioning (Sena and
Chandel, 2012); and mitocondrial metabolism. H2O2
alters protein function through post-translational mod-
ification (Finkel, 2012) of mitogen-activated protein
kinase, phosphatase and tensin homolog (Tonks, 2005;
Rojo et al., 2014), and others. Finally, autophagy in
response to cellular stress involving ROS leads to
programmed cell death (Scherz-Shouval and Elazar,
2011; Sena and Chandel, 2012; Pajares et al., 2017,
2018). However, ROS is among several other intracel-
lular signaling transducers that sustain and control
autophagy. Mitochondria-derived ROS indirectly acti-
vatesAMPprotein kinases, which are involved in several
signaling mechanisms, e.g., glucose metabolism and
inflammatory response. Indeed, AMP protein kinase
inhibitors have been suggested as a possible pharmaco-
therapy for neuroprotection and cancer, although no
compound reached the clinical stage (Viollet et al., 2010).
Immune cells destroy pathogens via theNOX2-mediated
oxidative burst, a key mechanism for antiviral, antipara-
sitic, and antibacterial responses (Arsenijevic et al., 2000),
and NOX-dependent regulation of toll-like receptor 4
(Ogier-Denis et al., 2008). In the nervous system, ROS
regulate synaptic plasticity at the cellular level by
modulating long-term potentiation as part of the learn-
ing process andmemory formation and/or maintenance.
Conversely, ROS dysregulation is involved in the impair-
ment of memory in the aged brain in neurodegenerative
diseases and dementia (Rojo et al., 2017, 2018).Moreover,
NOX3 is essential for audition because of its role in
otoconia formation, whereas different NO synthase iso-
forms play a role in blood pressure regulation, inflamma-
tion, and neuronal homeostasis. ROS toxifiers, e.g., MPO,
useH2O2 to oxidize the halides I
2, Br2, andCl2, resulting
in the subsequent hypopseudohalous acids with an
extreme oxidative reactivity (Casas et al., 2015). ROS
are therefore linked to several physiologic mechanisms,
and if essential, their dysregulation of off-target in-
hibition may lead to pathology or drug side effects,
respectively (Fig. 2).
III. ROS Generators and Toxifiers in Disease
For several ROS sources and toxifiers, clear target
validation has been demonstrated. For therapeutic
application, this has to be evaluated in light of their
physiologic function, possible side effects, and the
resulting risk-benefit ratio. Thus, in the following
sections, both of these aspects are discussed per target.
In general, acute indications such as ischemic stroke
(Kleinschnitz et al., 2010; Casas et al., 2017, 2019a,b)
and neurotrauma (Stover et al., 2014) appear safer than
those potentially requiring chronic therapy. Moreover,
since most targets are embedded in multiprotein sig-
naling modules (see above), multidrug approaches on
the same module, i.e., network pharmacology (Casas
et al., 2019a), with lower doses of each drug also seem
more promising and safer than single-target, single-
drug approaches.
A. Focus on Oxidases
1. NADPH Oxidase. Human NADPH oxidases are
a family of seven transmembrane proteins, i.e., five
mono-oxidases [NOX1, NOX2, NOX3, NOX4, andNOX5
(Wingler et al., 2011)] and two dual oxidases [DUOX1
and DUOX2 (van der Vliet et al., 2018)], each with
specific tissue distribution and physiologic functions. Of
these, NOX5 is the only one that is missing from the
mouse and rat genome and requires knockin mouse
models to be investigated in animal models, which has
resulted in the fact that this isoform is preclinically
understudied (Jha et al., 2017; Casas et al., 2019b;
Touyz et al., 2019a,b). NOX1–4 catalytic units, but not
NOX5, form a complex with the transmembrane protein
p22phox and, further, with different cytosolic regula-
tory (e.g., p67phox or NOXA1; the small G protein Rac)
and/or organizational protein partners (e.g., p47phox or
NOXO1). Most NOX isoforms produce O2
•2, whereas
NOX4 primarily leads to H2O2 (Peng et al., 2019). NOX
isoforms also differ regarding ROS generation kinetics
(low and high output), abundance (low and high expres-
sion levels), subunit requirements, and modes of activa-
tion (basally active or inactive). Concerning regulation,
NOX5 and the DUOXs stand out by being directly
calcium-activated (Rigutto et al., 2009; Touyz et al.,
2019b). However, unlike NOX5, DUOX produces H2O2
similar to NOX4; for details, see (Altenhöfer et al., 2015).
NOX1 is mainly expressed in the colon, where it
appears to play a role in gut immune regulation
(Schwerd et al., 2018). NOX2 was the first NOX to be
identified, originally named phagocytic oxidase glyco-
protein of 91 kDa, gp91
phox, and is mainly expressed in
leukocytes (eosinophils, neutrophils, macrophages). It
represents a vital component of the phagocytic oxidative
burst, and it has been suggested that it is involved in cell
proliferation, differentiation, and survival; contractility;
neuronal plasticity; and apoptosis (Diebold et al., 2015).
Moreover, inflammatory cytokines signal through mito-
chondrial ROS production lead to the activation of the
tumor necrotic factor receptor which promotes NF-kB
inflammatory response. NLRP3-dependent inflamma-
somes are activated through ROS, promoting a quick
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inflammatory response (Tschopp, 2011). NOX3 appears
to have the most restricted distribution, e.g., in the inner
ear, where it is essential for the formation of otoconia,
calcium carbonate crystals in the vestibule responsible
for the detection of linear acceleration, gravity, and
audition (Paffenholz et al., 2004; Kiss et al., 2006). A
recent study, however, showed NOX3 overexpression in
heart failure, suggesting new physiologic roles for this
isoform (Bkaily et al., 2019). Conversely, NOX4 has the
most ubiquitous distribution, including in the brain,
endothelium, kidney, muscle, and adipose tissue. There-
fore, NOX4 is constitutively active to preferentially
produce H2O2, as opposed to all other NOXs, which
produce superoxide. NOX4 plays a crucial role in cell
differentiation, e.g., in preadipocytes and endothelial
cells for angiogenesis (Schröder et al., 2009), as well as
in neural precursor cells for hippocampal neurogenesis
and memory formation (Choi et al., 2019; Yoshikawa
et al., 2019). NOX5 is physiologically expressed in
endothelium, spermatocytes, and lymphoid organs
(Jagnandan et al., 2007). In mice, a triple NOX1-2-4
knockout is viable and lacks a distinct phenotype
(Rezende et al., 2016). Thus, at least in mice under basal
conditions, NOX1-2-4 appear to be neither essential for
survival nor indispensable for basal physiology. This
scenario changes, of course, upon infection or under
stress condition (Odalys et al., 2015) or under stress
conditions (Zhang et al., 2010). DUOX1 and 2 are
expressed in the thyroid gland and are essential for
thyroid hormone synthesis (Moreno et al., 2002).
Regarding validated pathophysiological roles, NOX
enzymes are involved in several disease conditions
primarily based on NOX dysregulation (Casas et al.,
2015; Dao et al., 2015) (Table 1). Current drug develop-
ments for NOX inhibition focus on fibrotic and neuro-
vascular disease indications, with NOX1, 4, and 5 as the
main isoforms to be targeted (Casas et al., 2017; Jha
et al., 2017; Teixeira et al., 2017). NOX1 mutations are
also found in patients with inflammatory bowel dis-
eases (Scherz-Shouval and Elazar, 2011; Hayes et al.,
2015). Moreover, NOX1 appears to contribute to di-
abetic atherosclerosis (Di Marco et al., 2016) and
retinopathies (Wilkinson-Berka et al., 2014). As a proin-
flammatory gene, it is not surprising that NOX2 has
been suggested as a therapeutic target not only in
inflammatory diseases, i.e., acute respiratory distress
syndrome and chronic obstructive pulmonary disease,
but also in muscle and neurodegenerative disorders
such as Parkinson disease, amyotrophic lateral sclero-
sis, and schizophrenia, to name a few (Diebold et al.,
2015). Moreover, the genetic deletion of NOX2 may
reduce lungmetastasis (Xu et al., 2016; van derWeyden
Fig. 2. Role of ROS in physiology and disease. ROS plays a crucial role in several physiologic mechanisms, i.e., angiogenesis, cell signaling, immune
system, and memory formation. However, ROS have also been suggested to be part of several pathomechanisms because of a dysregulation of specific
ROS sources that leads to unphysiological 1) regulation, 2) location, and 3) amount of ROS produced. Our approach is focused on inhibition of ROS
formation through NOX, XO, MAO, NOS, and MPO. A parallel strategy focuses on the direct repair of ROS-induced damage through modulation of the
cGMP-forming enzyme sGC using both activators [sGC activators (sGCas)] and stimulators (sGCs). ONOO2, peroxynitrite.
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et al., 2017). Because of its role in the inner ear, NOX3
could be a key target for hearing loss. NOX4-derived
H2O2 leads to the pathologic fibrosis of liver (Lan et al.,
2015) and lung (Carnesecchi et al., 2011) and blood-
brain barrier breakdown and neurodegeneration upon
ischemic stroke (Kleinschnitz et al., 2010; Casas et al.,
2017, 2019a,b), but it is surprisingly protective in
atherosclerosis (Gray et al., 2016). NOX5 might be
a suitable target in cardiovascular pathologies (Touyz
et al., 2019a) and stroke (Casas et al., 2019b). DUOX2
and DUOXA2 loss-of-function mutations lead to con-
genital hypothyroidism (Weber et al., 2013) and can
be targeted for radiation-induced thyroid cancer
(Ameziane-El-Hassani et al., 2016).
Concerning safety-benefit considerations, pharmaco-
logical inhibition of DUOX2 should most likely be
circumvented to avoid hypothyroidism and bowel in-
flammation (Hayes et al., 2015). Also, the safety profile
of inhibiting NOX2 is controversial based on its role in
innate immunity (Sareila et al., 2011). A small residual
activity, however, may be sufficient to confer antimi-
crobial activity (Diebold et al., 2015), although the risk
of noninfectious complications similar to those in
patients with chronic granulomatous disease is less
clear (Henrickson et al., 2018). A potential concern
regarding NOX1 and NOX4 inhibition is to enhance
inflammation in the gut by inhibiting NOX1 and
diminishing the potential protective mechanisms of
NOX4 in vascular cells, thus promoting atherosclerosis
(Schürmann et al., 2015; Gray et al., 2016) as well as
enhancing the risks of kidney fibrosis (Nlandu Khodo
et al., 2012) and liver cancer (Crosas-Molist et al., 2017).
Acute indications such as ischemic stroke (Kleinschnitz
et al., 2010; Casas et al., 2017) are likely to have,
however, a low risk-benefit profile.
2. Nitric Oxide Synthases. NOSs are homodimeric
NADPH binding flavoheme proteins additionally regu-
lated by the redox-sensitive cofactor tetrahydrobiopterin
(H4Bip), calmodulin, and several othermodulatory inter-
actions (Nedvetsky et al., 2002) to convert L-arginine
(Schmidt et al., 1988) to NO. Three isoforms exist, and
they were initially named according to their first
observed cellular/tissue localization or expressional
regulation, i.e., neuronal, inducible, and endothelial
(i.e., NOS1, NOS2, and NOS3) (Schmidt et al., 1991;
Förstermann et al., 1992; Chakrabarti et al., 2012; Liu
et al., 2012; Caviedes et al., 2017). Qualitatively, three
functional states need to be differentiated: 1) physio-
logic NO formation signaling via sGC into cGMP and
PKG (Schmidt and Walter, 1994); 2) excessive NO
formation leading to cellular and tissue damage
(Kleinschnitz et al., 2016), e.g., in stroke; and 3)
uncoupled states of NOS in which the activation of
oxygen is not coupled to the oxidation of arginine but
results in leakage of ROS, such as in endothelial
dysfunction and hypertension (Li et al., 2015).
Several mechanisms have been suggested to cause
NOS uncoupling, for which oxidation of H4Bip (tetrahy-
drobiopterin) to H2Bip (dihydrobiopterin) appears to be
crucial (Schmidt et al., 1992; Bömmel et al., 1998).
H2Bip leads to enzyme monomerization (Reif et al.,
1999) and inhibition of activity (Kotsonis et al., 1999). In
turn, supplementation with arginine (Schramm et al.,
2002) and/or H4Bip in vitro (Kotsonis et al., 2000) or
in vivo (Moens et al., 2011) recouples NOS and restores
NO-cGMP signaling and function. An alternative
approach to substituting H4Bip may be to facilitate
its endogenous recycling via dihydrofolate reductase
(Crabtree et al., 2009; Crabtree and Channon, 2011).
Counterproductive competition of folic acid with H4Bip
does not seem to occur. Another pathophysiologically
relevant event is the accumulation of methylated
arginine analogs, in particular asymmetric dimethylar-
ginine (Antoniades et al., 2009), which inhibitsNOS and
appears to be an independent cardiovascular risk factor.
This mechanism may be a rationale to clinically sub-
stitute L-arginine (Schramm et al., 2002) or L-citrulline
(subsequently converted to L-arginine) to compete
against asymmetric dimethylarginine–induced NOS
inhibition, despite cellular L-arginine being sufficiently
TABLE 1
NOX isoforms: function and potential pathologic role
Functional
NOX Loss of Function Potential Role of Excessive Activity in Disease
NOX1 Increased susceptibility for inflammatory bowel disease
(NOX1)
Ischemic retinal diseases; atherosclerosis
NOX2 Chronic granulomatous disease (NOX2, CYBA, NCF1,
NCF2, and NCF4), increased incidence of lupus (NOX2,
NCF1)
Metastasis, acute lung inflammation, chronic obstructive pulmonary
disease, pulmonary hypertension, and neurodegenerative diseases
(Alzheimer and Parkinson disease); pancreatitis
NOX3 Not described in humans., balance defects due to lack of
otoconia in rodents (CYBA, NOXO1, and NOX3)
Hearing loss
NOX4 Not described in humans, no phenotype in mouse
knockouts
Stroke, diabetic nephropathy
NOX5 Not described in humans, no animal knockouts, not
expressed in rodents
Cardiovascular disease





Hypothyroidism (DUOX2, DUOXA2), increased
susceptibility for inflammatory bowel disease (DUOX2).
Cancer
CYBA, cytochrome b-245 light chain; NCF, neutrophil cytosol factor.
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high to also thoroughly saturate NOS under disease
conditions. Besides augmenting NO synthesis and sub-
sequent cGMP formation, there may be situations in
which NO levels are unphysiologically high, causing
disease states, most likely in a cGMP-independent
manner. These include inflammatory and hypoxic
states. Attempts to exploit previous conditions clinically
have all failed. Conversely, NOS inhibition using anti-
pterins (Fröhlich et al., 1999; Kotsonis et al., 2001), such
as ronopterin, in neurotrauma (Stover et al., 2014) and
stroke (Kleinschnitz et al., 2016; Casas et al., 2019a)
may be promising. Future pivotal clinical trials [No
Synthase in Traumatic Brain Injury (NOSTRA) III,
NCT02794168] to be finalized in 2020 will tell.
Concerning risk-benefit profile, NOS inhibition
(chronic inhibition, in particular) could be detrimental
for patients suffering from cardiovascular and renal
diseases due to endothelial dysfunction, i.e., vasocon-
striction, hypertension, atherosclerosis, and insulin re-
sistance. Thus, acute indications seem to be more
promising.
3. Xanthine Oxidase. Xanthine oxidoreductase is
a terminal enzyme in the purine catabolic pathway that
catalyzes the conversion of hypoxanthine to xanthine
and then to uric acid (UA). XOR exists in two isoforms:
xanthine oxidase (XO) and xanthine dehydrogenase
(XDH). To note, XDH and XO are interconvertible,
i.e., XDH can be converted into XO (Battelli et al.,
1973). Thus, not only is XO an ROS-generating enzyme,
but oxidative modification would convert residual XDH
into XO to produce more ROS.
Physiologically, UA can directly activate the NACHT,
LRR, and PYD domain–containing protein 3 inflamma-
some, resulting in toll-like receptor–independent pro-
duction of interleukin (IL)-1b and IL-18 (Martinon
et al., 2006). This is not only restricted to urate crystals
but also an activity of soluble UA (Braga et al., 2017).
Thus, UA adds a further element of complexity into
possible ROS-independent activities of XO. Moreover,
UA is not just a biomarker of XO activation, but it has
also been indicated as a potent antioxidant (Ames,
1989).
The best-known pathologic role of XOR is indepen-
dent of ROS in the accumulation of uric acid in gout.
Text mining analysis presents ischemia-reperfusion
injury (Granger et al., 1981) as the primary disease
concept associated to XO (841 hits), followed by tumor
development (422) and several cardiovascular diseases
(CVD), including hypertension (169), diabetes (143),
myocardial ischemia (125), myocardial infarction (101),
atherosclerosis (118), coronary disease (115), and heart
failure (111). XO can be activated in reperfusion because
of the high availability of substrates. Angiotensin II can
induce XO levels in aortic endothelial cells in vitro
(Landmesser et al., 2007), which may be relevant in
CVD states. For example, in patients with coronary
artery disease, XO is activated along with NOX
(Spiekermann et al., 2003), and plasma XO levels are
associated with left ventricular hypertrophy in hyper-
tension (Butts et al., 2019). Assuming that XO activation
is a causal mechanism in disease, one might expect that
UA would correlate with disease or disease severity.
Despite all evidence of XO in CVD, the association of
hyperuricemia and CVD has remained unclear and
controversial (Feig et al., 2006). A positive correlation
between UA levels and disease was observed for chronic
kidney disease (Wang et al., 2018a), peripheral artery
disease (Wang et al., 2018a), atrial fibrillation (Tamariz
et al., 2014), and nonalcoholic fatty liver disease
(Jaruvongvanich et al., 2017). In several other condi-
tions, however, meta-analyses resulted in a negative
correlation between UA and disease, including neuro-
logic or psychiatric diseases such as Parkinson (Wei
et al., 2018), Alzheimer (Mullan et al., 2018), depression
(Bartoli et al., 2018), autism (Wen et al., 2017), and
dementia (Khan et al., 2016). XO is also elevated in
tissues and serum after viral or bacterial infection
(Akaike et al., 1990). The induction of XO by pathogens
is probably mediated by interferon (IFN), which acts as
an XO inducer at the transcriptional level (Ghezzi et al.,
1984). These findings may explain infections as risk
factors for CVD.
For a risk-benefit profile of XO as a target, safety
appears to be high based on the decade-long experience
with antigout medication. It has been suggested that
close monitoring should be taken into account in
patients with impaired renal function (Jordan and
Gresser, 2018). A recent study argues, however, against
such a risk (Vargas-Santos et al., 2018).
4. Monoamine Oxidase. MAOs are flavin-containing
enzymes located in the outer mitochondrial membrane.
They catalyze the oxidative deamination of both endog-
enous and exogenous amines, especially modulating the
metabolism of neurotransmitters and several drugs.
During this process, MAOs generate a significant
amount of H2O2 as a by-product and, indirectly, alde-
hyde and ammonia (Casas et al., 2015). MAOs exist in
two isoforms, A and B, which differ in structure,
substrate preference, inhibitor specificity, and tissue
distribution (Binda et al., 2002; De Colibus et al., 2005;
Finberg, 2014). MAO-dependent increases in H2O2
formation have been observed in isolated skeletal and
cardiac myocytes (Kaludercic et al., 2010, 2014; Sorato
et al., 2014; Deshwal et al., 2018); increased expression
ofMAO-B, but notMAO-A, has been observed in various
other tissues upon aging, including brain (Fowler et al.,
1997).
In mood disorder models related to stress and gluco-
corticoid administration, a decrease in neurotransmit-
ter levels and the preferred utilization of serotonin and
noradrenaline by MAO-A led to the development of
MAO-A inhibitors as antidepressants. Clinical data are,
however, not yet available. MAO-A–dependent ROS
formation contributes to muscle dystrophy and other
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pathologies (Sorato et al., 2014), such us prostate
tumorigenesis and cancer metastasis. Pharmacological
or genetic inhibition of MAO-A reduced or even elimi-
nated prostate tumor growth andmetastasis in prostate
cancer mouse models, whereas high MAO-A expression
in cancer tissues correlated with worse clinical out-
comes in patients (Wu et al., 2014a). These findings
suggest that MAO-A has potential as a therapeutic
target in cancer treatment. On the other hand, MAO-B
is increased in Huntington, Alzheimer, and Parkinson
diseases (Kumar et al., 2003; Gulyás et al., 2011;
Krzyszton-Russjan et al., 2013; Ooi et al., 2015), and
inhibition of MAO-B is indicated in the treatment of
Parkinson disease because of its efficacy in sparing
endogenous dopamine (Bortolato and Shih, 2011; Fisar,
2016). Several reports suggest that, in addition to
modulating neurotransmitter levels, MAO-dependent
ROS generation promotes the development of neurode-
generative disorders by causing oxidative damage to
neurons (Youdim et al., 2006; Bortolato et al., 2008).
Additionally, MAO contributes to cardiovascular dis-
ease, including ischemia-reperfusion injury (Bianchi
et al., 2005; Pchejetski et al., 2007; Carpi et al., 2009),
pressure overload (Kaludercic et al., 2010, 2014), di-
abetic cardiomyopathy (Deshwal et al., 2018), post-
operative atrial fibrillation (Anderson et al., 2014),
and vascular dysfunction (Sturza et al., 2013). MAO
activity is increased in the left and right ventricles from
patients with ischemic heart disease (Manni et al.,
2016). The mechanisms underlying MAO toxicity have
mostly been attributed to excessive H2O2 and aldehyde
generation, which leads to impaired mitochondria-
endoplasmic reticulum cross talk and cardiomyocyte
death (Kaludercic et al., 2014; Deshwal et al., 2018).
Based on the known side effects ofMAO inhibitors, their
risk-benefit profile for novel severe indications appears
to be beneficial.
B. Focus on Toxifiers
1. Myeloperoxidase. Myeloperoxidase is heme pro-
tein (Fiedler et al., 2000) that is located primarily in
neutrophils and, to a lesser extent, in monocytes
(Bainton et al., 1971) and uses H2O2 to oxidize the
halides I2, Br2, and Cl2 (but not F2) and the pseudo-
halide SCN2 to give the corresponding hypohalous and
hypopseudohalous acids, which have high oxidative
reactivity (Jantschko et al., 2005). Besides hypo(pseudo)
halous species (HOSCN), MPO produces other potent
oxidative compounds, such as the nitrous radical (NO•)
and peroxynitrite (Eiserich et al., 2002). The highly
oxidative product, hypochlorous acid, has an essential
role in immunity by causing oxidative damage to bio-
molecules of pathogens phagocytosed by neutrophils
(Odell and Segal, 1988) and stimulating the release of
inflammatorymediators. By oxidizing serotonin,MPOnot
only impairs physiologic functions of serotonin but also
generates the neurotoxic compound tryptamine-4,5-dione
(Ximenes et al., 2009). Besides, MPO-catalyzed oxidation
of uric acid has been reported in patients with gout, in
whom reactive metabolites from urate may contribute to
the pathology of gout (Stamp et al., 2012) and may be
implicated in several chronic inflammatory syndromes
related to the central nervous system, cardiovascular
system, respiratory system, and renal system, including
glomerular and tubulointerstitial disorders (Klebanoff,
2005). MPO is involved in the development of atheroscle-
rosis (Libby et al., 2011), which is related to the over-
expression of the enzyme, and chloro-tyrosine (ClTyr) has
been considered as a potential biomarker for CVD (see
section VI. Biomarkers of ROS). MPO-dependent oxida-
tive modification makes high-density lipoprotein dysfunc-
tional, i.e., unable to contribute to cholesterol efflux
(Smith, 2010). In gestational hypertension, MPO medi-
ates endothelial dysfunction by directly consuming NO
(Nicholls and Hazen, 2005; Rocha-Penha et al., 2017).
However, MPO-deficient mice do not show enhanced
endothelial function compared with wild-type mice, even
when provoked with lipopolysaccharide (Golubinskaya
et al., 2014). Moreover, high levels of MPO have been
detected in brain tissues of patients with several neuro-
degenerative disorders (Gellhaar et al., 2017), such as
Parkinson (Choi et al., 2005), Huntington (Choi et al.,
2005), Alzheimer (Green et al., 2004), and multiple
sclerosis (Nagra et al., 1997). However, mice lacking
MPO are more susceptible to experimental autoimmune
encephalomyelitis (Brennan et al., 2001). Studies on
epileptic brains suggested that MPO is the key source of
chlorination stress in epileptogenesis (Ray and Katyal,
2016). Patients with cystic fibrosis show high amounts of
MPO in lung tissue. Moreover, the damaged tissues
contain significant levels of 3-chlorotyrosine, 3,39-dityr-
osine, and nitrotyrosine (van der Weyden et al., 2017).
Finally, MPO correlates with several types of cancers,
i.e., lung (Li et al., 2014), renal (Ramsaransing et al.,
2003), esophageal (Inayama et al., 2007), epithelial
ovarian (Saed et al., 2010), bladder (Hung et al., 2004),
larynx (Cascorbi et al., 2000), and acute leukemia (Kim
et al., 2012).
IV. Pharmacological Modulation of ROS
A. Inhibition of ROS Formation
1. NADPH Oxidase Inhibitors. Conventional meth-
ods used to measure NOX activity are prone to
artifacts (Maghzal et al., 2012; Dao et al., 2020), and
particular attention is required for assays used to
measure H2O2 and O2
• , such as L-012, luminol, or
Amplex Red, because of their lack of specificity and
further shortcomings (Dikalov and Harrison, 2014;
Zielonka et al., 2014). Thus, methods to eliminate
nonspecific hits are essential. This type of approach
has indeed limited many reported NOX inhibitors,
including apocynin, VAS2870, 2-acetylphenothiazine
(ML-171), GKT136901.
On the Clinical Pharmacology of Reactive Oxygen Species 809
Small-molecule NOX inhibitors are already well de-
scribed in the literature (Jaquet et al., 2009; Altenhöfer
et al., 2015). GSK2795039 was identified after a high-
throughput screening performed by GlaxoSmithKline,
which it had claimed in international patent application
WO/2012/170752 or WO/2011/075559. Its IC50 is in the
sub-micromolar range for NOX2, and it is inactive
against other NOX isoforms. GSK2795039 is orally
bioavailable, it can dose-dependently block NOX2 in
amodel of paw inflammation, and has a protective effect
in the cerulein mouse model of pancreatitis. CPP11G
and CPP11H are two recently discovered in silico–
modeled NOX2 inhibitors that can improve endothelial
cell inflammation and vessel dysfunction by abolishing
tumor necrotic factor a-induced ROS production (Li
et al., 2019). Thioridazine and several other phenothia-
zines, some of them already marketed for different
indications (i.e., antipsychotic), are moderate inhibitors
of NOX1–5 that are in the low micromolar range.
Thioridazine is a useful pharmacological tool to inhibit
NOX in vivo, as it was shown to mitigate O2
2 production
in the spinal cord of a mouse model of amyotrophic
lateral sclerosis (ALS). However, it did not show in-
creased survival (Seredenina et al., 2016). Unfortu-
nately, N-substituted phenothiazines are molecules
with numerous described modes of action and, there-
fore, several off-target effects to be considered. Ewha-
18278 (APX-115) inhibits NOX1, NOX2, and NOX4 in
the low micromolar range. Ewha-18278 is orally avail-
able and shows therapeutic benefit in a mouse model of
ovariectomy-induced osteoporosis (Joo et al., 2016) and
mouse models of diabetic nephropathy (Cha et al.,
2017).
NADPHoxidase inhibitors have attracted international
patent submissions starting in 1990, when small compa-
nies and academia took the lead, whereas large pharma-
ceutical entities were mostly absent. The premiere
patentee is the French company Genkyotex SA, which
has built a pipeline of NOX inhibitors, although recently
promising compounds have been patented by Actelion
(MX2017016908) and Glenmark (WO2018203298).
Although the earliest Genkyotex research had fo-
cused on the NOX2 isoform, the lead candidate
GKT137831 (Setanaxib, but also recently abbreviated
to GKT-831) is claimed as a NOX1/4 dual inhibitor. So
far, it is one of the few NADPH oxidase inhibitors
besides APX-115 (see below) that has reached the
clinical trial stage. Apocynin, a methoxycatechol in-
vestigated by the Medical University of Lodz by
inhalation in chronic congestive pulmonary disease
and patients with asthma, is far from being NOX-
specific and, thus, is not considered a NOX inhibitor in
this context. GKT-831 is being developed for diabetic
nephropathy in its first clinical efficacy studies, and
in November 2015, an orphan drug designation was
obtained in the United States and Europe for systemic
sclerosis.
During the phase I program, this candidate exhibited
a favorable pharmacokinetic profile that was dose-
proportional over the 10- to 900-mg range. In the sub-
sequent phase II trial (NCT02010242) in 155 patients
with diabetic nephropathy and residual albuminuria,
despite maximal inhibition of the renin-angiotensin-
aldosterone system, the primary endpoint (reduction of
albuminuria) was not reached. A phase II study with
GKT-831 (400 mg once or twice daily for 24 weeks) in
patients with primary biliary cholangitis (an orphan
disease) started in June 2017 (NCT03226067) and met
its primary and secondary interim efficacy endpoints in
November 2018. Success in this indication could expand
the clinical applications ofGKT-831 to other liver fibrosis
opportunities, such as nonalcoholic steatohepatitis.
In 2018, Genkyotex announced a phase II clinical trial
with GKT-831 in patients with idiopathic pulmonary
fibrosis, an indication that Genkyotex had initially
chosen not to pursue. This indication follows another
phase II trial in type 1 diabetes and kidney disease
launched in Australia (Table 2). APX-115 is also
clinically developed for the same indication, i.e., diabetic
nephropathy (Lee et al., 2020), moving from phase I to II,
which was originally announced for 2019 but has not yet
been listed in clinicaltrials.gov.
Additional preclinical-stage compounds from the
extensive Genkyotex NOX inhibitor portfolio, such as
GKT136901, are currently under evaluation (Teixeira
et al., 2017). Evidence in eye disease has been preclini-
cally published in retinopathy of prematurity (Deliyanti
and Wilkinson-Berka, 2015) but could very likely be
extended to diabetic retinopathy. VAS2870, a NOX4
inhibitor from Vasopharm (claimed in WO/2005/
111041), has recently been reported to inhibit the
proliferation of retinal pigment epithelial cells after
their epithelial-to-mesenchymal transition, a signifi-
cant pathologic change involved in proliferative vitre-
oretinopathy (Yang et al., 2018). The Swedish company
Glucox Biotech AB is also focused on NOX4 inhibitors
and is reported to be looking into diabetes, Marfan
syndrome, stroke, and cancer. GLX351322 (Anvari et al.,
2015), GLX7013107, and GLX7013114 (GLX114) (Wang
et al., 2018b) are compounds that are likely to be covered
by the substantial intellectual property portfolio in
Glucox’s name: WO/2016/133446, WO/2016/096720,
WO/2014/064118, WO/2013/135803, WO/2008/008033,
andWO/2003/087399. A remarkable range of less appar-
ent indications for NOX inhibitors has been claimed by
academia: cardiac arrhythmia (WO/2013/158782, Uni-
versity of California), muscular dystrophies (WO/2013/
078261, University of Maryland), cataract and presby-
opia (WO/2009/044294, Université de Genève), and
a broad range of psychiatric disorders (WO/2009/
052454, University of California). So far, it is not
possible to estimate what clinical potential NOX
inhibitors could have in these applications. Similarly,
1) the tetrahydroisoquinoline NOX2 inhibitors from
810 Casas et al.
Pittsburgh University (WO/2014/179592), 2) bi- and
triaromatic compounds claimed by the University of
Surrey (WO/2013/038136), and finally 3) quinazolines
(WO/2013/181135, WO/2012/058211) and piperazines
(WO/2012/173952) from Emory University merit sig-
nificant attention (Fig. 3).
a. Limitations of NOX inhibitors. The observed
protected role of NOX inhibition in several preclinical
studies identifies NOX isoforms as a promising thera-
peutic target. However, the specificity of NOX inhibitors
remains controversial. Widely used compounds such as
diphenyleneiodonium chloride, ebselen, and VAS2870
inhibit all NOXs in similarmicromolar or sub-micromolar
ranges, compromising their usefulness as isoform-
specific experimental tools. Moreover, apocynin, fre-
quently used as a NOX2 inhibitor, resulted in complete
inactivation of all NOXs, suggesting that its anti-
inflammatory therapeutic properties cannot be at-
tributed to NOX inhibition. Controversially, a recent
report has shown that GKT137831 and its close analog,
GKT136901, are indeed not active on NOX enzymes
(Augsburger et al., 2019) but rather to an oxidant
scavenging effect, as previously suggested (Schildknecht
et al., 2014). However, several previous studies and in-
house experimentation showed its NOX1/4 activity
(Altenhöfer et al., 2015). Although the field is intensively
criticized, highly specific compounds recently entered the
pipeline. GSK2795039 (Hirano et al., 2015) remains the
first NOX2 competitive inhibitor in which in vivo efficacy
was thoroughly studied, although other compounds,
i.e., CPP11G and CPP11H, are now in the early stages
of development (Li et al., 2019). Moreover, GLX7013114
(Glucox, Sweden) has shown a NOX4-specific profile,
whereas ML090 resulted in a potent NOX5 inhibitor
(Casas et al., 2019b). An immediately applicable NOX
inhibitor panel has been recently proposed that suggests
ML171, VAS2870, M13, andML090 as NOX1, 2, 4, and
5 inhibitors, respectively (at specific concentrations),
TABLE 2
Inhibition of ROS formation and toxification: translation to the clinics





GKT137831 Idiopathic pulmonary fibrosis NCT03865927 Phase II
Type 2 diabetes and albuminuria NCT02010242 Completed (phase III
in preparation)





L-NMMA GLP-2–mediated intestinal lipoprotein release NCT03534661 Phase I
Non–small-cell lung cancer, malignant
melanoma, head and neck squamous cell
carcinoma (three more)
NCT03236935 Phase I
Metastatic triple negative breast cancer
patients
NCT02834403 Phase II
2-Iminobiotin Perinatal asphyxia NCT01626924 Phase II, recently
terminated
Out-of-hospital cardiac arrest NCT02836340 Phase II
VAS203 Traumatic brain injury NCT02794168 Phase III
XO XO
inhibitor
Allopurinol (approved) Chronic gout — —
Ischemic stroke and transient ischemic attack NCT02122718 Phase IV
Hypoxic-ischemic brain injury on
neurocognitive outcome
NCT03162653 Phase III
Complications of renal transplant NCT01332799 Phase IV
Congestive heart failure NCT00181155 Phase II
Chronic heart failure NCT00997542 Phase IV
Febuxostat (approved) Gout — —
Endothelial function, cardiovascular system,
hypertension
NCT03395977 N/A
Hematologic malignancies of pediatric patients
and adults
NCT03605212 Phase II
Chronic renal disease NCT03425708 Phase IV
Topiroxostat Diabetic nephropathy NCT02327754 Phase II
Hyperuricemia NCT02837198 Phase II
MAO MAO
inhibitor
Safinamide, selegiline Parkinson disease — —
Rasagiline (approved) Macula-off retinal detachment NCT02068625 Phase IV
Toloxatone (approved) Depression — —
Pirlindole (approved) Depression, anxiety — —
Phenelzine, isocarboxazid,
tranylcypromine (approved)
Major depressive disorder — —
Moclobemide (approved) Addiction and major depression — —
MPO MPO
inhibitor
AZD3241 Parkinson disease NCT01527695,
NCT01603069
Phase II
Multiple system atrophy NCT02388295 Phase II (negative)
AZD4831 Heart failure NCT03756285,
NCT03611153
Phase II
GLP-2, glucagon-like peptide-2; L-NMMA, L-NG-monomethyl arginine.
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allowing NOX-dependent target validation in scenar-
ios in which using knockout/knockin animals is not
possible (Dao et al., 2020). Thus, IC50 values of these
compounds should be carefully considered for experimen-
tal design to ensure a suitable concentration range for
both in vivo and in vitro studies. Despite recent advances,
precise systematic evaluation using multiple redox test
systems is still required to identify novel compounds to
wisely target NOXs and their pathologic role.
2. NO Synthase Inhibitors. A large number of nitric
oxide synthase inhibitors with various degrees of
selectivity for NOS isoenzymes are available and
claimed in patents. However, few have reached the
clinical trial stage, and not all of these meet the criteria
for pharmaceutical development ability. This applies
primarily to the numerous derivatives of L-arginine, the
physiologic NOS substrate:
• NG-monomethyl-L-arginine (tilarginine; the ar-
chetypal, relatively nonselective NOS inhibitor,
also endogenous),
• NG-nitro-L-arginine methyl ester (inactive prodrug
of NG-nitro-L-arginine) (Pfeiffer et al., 1996), and
• other nitroarginine esters (L-NG-benzylarginine,
L-NG-aminoarginine, iminoethylornithine).
Clinical trials have been conducted withmost of these
compounds. Many were conducted in stand-alone set-
tings, e.g., tilarginine was tested in acute myocardial
infarction complicated by refractory cardiogenic shock
(the TRIUMPH trial, NCT00112281), which failed to
reduce mortality (Alexander et al., 2007). Recently,
L-arginine–derived NOS inhibitors have been employed
as potentially synergistic adjuncts to other candidate
compounds, such as tilarginine, to block blood flow in
the gut to prevent glucagon-like peptide-2 release from
gut lipid stores (ongoing study sponsored by the Toronto
University Health Network, NCT03534661). Addition-
ally, tilarginine is also used to treat cancers when
combined with the anti–programmed death-1 mono-
clonal antibody pembrolizumab (Merck & Co.’s Key-
truda), again as a blood flow disruptor (NCT03236935;
phase Ib). Moreover, specific inducible NOS inhibitors,
i.e., acetamidine derivatives, have been synthesized
and evaluated that show high isoform specificity under
sub-micromolar concentrations (Fantacuzzi et al.,
2016). L-S-methylthiocitrulline is another amino acid
derivative that is selective for neuronal NO synthase
and has been reported in a phase II clinical study.
However, stability issues and (more importantly) lack of
patentability will prevent the further development of
these compounds into drugs. The situation is different
for 2-iminobiotin, a selective neuronal NOS and in-
ducible NOS inhibitor that was originally patented by
the Amsterdam University Medical Center for the
treatment and prevention of perinatal asphyxia (WO/
2001/074351) and is currently being developed by the
Dutch company Neurophyxia B.V. The company has
published an international patent application claiming
the compound for cerebral hypoxia-ischemia and reper-
fusion injury (WO/2017/105237) and other pharmaceu-
tical formulations (WO/2011/149349). The company has
been recruiting patients for a phase II study to prevent
hypoxic brain injury in patients with out-of-hospital
cardiac arrest (NCT02836340) using an intravenous
administration within 6 hours after the event. The
current status of the trial is unknown.
The most advanced NOS inhibitor is Vasopharm Biotech
GmbH’s ronopterin (VAS203; 4-aminotetrahydrobiopterine).
It entered phase III development for moderate and
severe closed traumatic brain injury in September 2016;
recruitment for the 220-patient NOSTRA-III study
(NCT02794168) was 50% complete in March 2018, with
35 European neurotrauma centers in Germany, Aus-
tria, France, United Kingdom, and Spain participating
(Fig. 4). NOSTRA-III, which is due for completion in
November 2019, aims to confirm the data from the
phase IIa NOSTRA trial (NCT02012582), in which
ronopterin produced a clinically significant two-point
improvement in the extended Glasgow Outcomes Score
—a clinically significant benefit (Stover et al., 2014).
Vasopharm holds several patent applications on
ronopterin and related pteridines (WO/2005/037286 and
Fig. 3. NADPH oxidase isoforms with clinical potential. NOX1 and 4 need a complete protein complex to be fully activated and generate superoxide
(O2
2; in the case of NOX1) and H2O2 (in the case of NOX4). NOX5 stands out by being directly calcium-activated and also producing superoxide. Under
several pathophysiological conditions, all NADPH oxidase isoforms can be directly induced. Pan-inhibitors, dual NOX1/4 inhibitors, and specific NOX4
and NOX5 inhibitors are shown based on their current status, i.e., under clinical testing or preclinical development.
812 Casas et al.
WO/2004/084906). With no drug treatment approved
explicitly for neuroprotection after traumatic brain injury,
considerable hope rests on this drug candidate (Table 2).
3. Xanthine Oxidoreductase Inhibitors. As men-
tioned earlier, the first XO inhibitor developed was
allopurinol, currently used for the treatment of gout,
followed by its derivative, oxypurinol. However, adverse
events and the need for high doses (in the range of 300
mg) prompted research for novel XO inhibitors. Indeed,
febuxostat has been approved by the Food and Drug
Administration in 2009 and can be given at lower doses
for hyperuricemia in adults suffering from gout, to-
gether with other drugs also being tested, i.e., top-
iroxostat. For this reason, many current trials test
febuxostat rather than allopurinol. An earlier meta-
analysis on congestive heart failure and other CVDs has
shown an effect of allopurinol or oxypurinol on surro-
gate markers, including vascular function, as well as on
malondialdehyde, a biomarker of excess ROS (Higgins
et al., 2012). A recent trial with allopurinol in patients
with chronic heart failure did not show an improvement
in arterial stiffness, but it is important to note that
these patients were not hyperuricemic (Alem et al.,
2018). In August 2018, theUniversity of Iowa completed
the Xanthine Oxidase Inhibition in Renal Transplant
Recipients trial (NCT01332799) to evaluate the effect of
daily allopurinol on cardiovascular events and endothe-
lial function in these vulnerable patients. This is in line
with a small study conducted by the University of
Dundee (NCT00688480) that investigated whether
allopurinol can reduce both left ventricular hypertrophy
and endothelial dysfunction in cardiovascular patients
with renal dysfunction. Two earlier United States–
based studies (NCT00181155, NCT00997542) had fo-
cused on heart failure. There are a few active clinical
trials that focus on the effect of allopurinol as a suppres-
sor of ROS generation: 1) XILO-FIST (NCT02122718),
managed by the UK National Health System and the
University of Glasgow, investigates whether allopurinol
can reduce the formation of white matter hyperinten-
sities, cardiac hypertrophy, and the onset of hypertonia
after an ischemic stroke. The phase IV trial, which plans
to randomize 464 patients, commenced inMay 2014 and
is estimated to last until September 2020 (Dawson
et al., 2018). 2) University Hospital Tübingen, in
collaboration with a dozen other European clinical
centers, is recruiting for ALBINO. This phase III trial
(NCT03162653), planned for 646 participants, inves-
tigates the drug’s efficacy and safetywhen administered
immediately after birth to near-term infants with
hypoxic-ischemic encephalopathy, in addition to stan-
dard hypothermic treatment. The estimated study
completion date is December 2020. 3) A prospective
randomized clinical trial with allopurinol versus top-
iroxostat (another XO inhibitor) in patientswith chronic
heart failure is currently ongoing in Japan (Sakuma
et al., 2018). Nonpurine xanthine oxidase inhibitors
have been developed to avoid the many side effects of
allopurinol, but none has quite matched it in terms of
efficacy. Of relevance are febuxostat (marketed as
Uloric), which was discovered at the Japanese pharma-
ceutical company Teijin in 1998 and licensed to Takeda
Pharmaceuticals and Ipsen, and topiroxostat (approval
in Japan in 2013; sold as Topiloric and Uriadec).
Fig. 4. Therapeutic targeting of NO-sGC signaling in physiology and disease. Under physiologic conditions, NO produced by NOS1 and 3 activates the
sGC, which results in cGMP formation and cell signaling regulation. However, dysregulation of this mechanism leads to increase NO and superoxide
production through NOS1 and NOS3, respectively, resulting in nitrative damage. In oxidative stress conditions, the sGC heme can be either oxidized or
removed (apo-sGC) and, therefore, is no longer an active enzyme. NOS inhibitors, sGC stimulators, and activators are shown based on their current
status, i.e., already marketed, under clinical testing, or under preclinical development. L-NAME, L-arginine methyl ester; L-NMMA, L-NG-
monomethyl arginine; SMTC, S-methyl-L-thiocitrulline; un-NOS3, uncouple endothelial NO synthase.
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Patenting for xanthine oxidase inhibitors reveals low
interest for new agents, which are almost exclusively
focused on the treatment of gout (Fig. 5). Recent
exceptions point toward applications in which ROS
might be involved, including cancer (WO/2017/142091)
and angina (WO/2010/136823). Thus, it seems highly
unlikely that xanthine oxidase inhibitors would be
developed into drugs that specifically address unde-
sired ROS formation, not only because of side effects but
also because of the possibility to interfere with purine
metabolism (Table 2).
4. Monoamine Oxidase Inhibitors. After the initial
compounds, clorgyline and deprenyl, a wide array of
MAO inhibitors have been developed, including the
reversible inhibitor moclobemide for MAO-A. Revers-
ible inhibition should be less prone to adverse effects
and devoid of overdose toxicity (Lum and Stahl, 2012).
However, the high degree of inhibition required for the
pharmacological effects might be more challenging to
achieve, since the administered inhibitor has to com-
pete with endogenous substrates. The monoamine
oxidase inhibitor that has been most intensely investi-
gated for potential neuroprotective effects is rasagiline,
an irreversibleMAO-B inhibitor that has been approved
as a symptomatic treatment of Parkinson disease.
Efforts to prove an additional disease-modifying effect
in this disease (NCT00256204) yielded ambiguous
results, which caused the US Food and Drug Adminis-
tration to refuse the corresponding application for an
approved extension. Although rasagiline did seem to
show indications of such a neuroprotective effect in
ALS when added to the standard treatment riluzole
(Ludolph et al., 2018), another trial found no effect on
disease progression after 1 year of treatment (Statland
et al., 2019). A phase IV clinical study investigating
rasagiline for neuroprotection in retinal detachment
(NCT02068625), suggested by data obtained with a
mouse model (Eigeldinger-Berthou et al., 2012), was
prematurely terminated on 31 December 2018 because
of persistent recruitment difficulties. Its termination
was reported in February 2019, although no further
information regarding outcome has been provided yet
(Table 2). Besides, multimodal compounds have been
developed that combine the propargyl moiety of MAO
inhibitors with compounds targeting other processes
involved in neurodegenerative disorders. The best
examples are ladostigil, which adds the anticholines-
terase action of rivastigmine to rasagiline (Youdim
et al., 2006). The latest MAO-B inhibitor released on
the market is safinamide, a highly selective and re-
versible inhibitor of monoamine oxidase B. It is cur-
rently being used as an add-on therapy in patients with
mid- to late-stage fluctuating Parkinson disease (Fabbri
et al., 2015). The cardioprotective and antitumorigenic
effects of MAO inhibitors are well established in animal
models, so it is tempting to speculate whether the
currently available compounds could be repurposed for
the treatment of these pathologies. Notably, among the
Fig. 5. XO as a therapeutic target. In normoxic conditions, ATP levels remain stable, whereas under hypoxia, ATP is catabolized, leading to
accumulation of purines, i.e., inosine and hypoxanthine. XDH under oxidative conditions gets oxidized, leading to XO. Later, XO catabolizes purines to
uric acid while generating ROS. Uric acid can directly activate inflammatory pathways, resulting in toll-like receptor–independent production of IL-1b
and IL-18, activation of NACHT, LRR and PYD domains-containing protein 3 (NALP3) and, therefore, inflammation and oxidative stress coursing with
the disease. XO inhibitors are shown based on their current status, i.e., already marketed or under preclinical development.
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mitochondrial sources of ROS, MAO inhibition repre-
sents the only pharmacological approach devoid of effects
on the vital functions of mitochondria related to energy
conservation. This critical advantage is further enhanced
by the clinical availability of MAO inhibitors, which is
not the case with any othermitochondrial source of ROS.
The availability of selective and reversible MAO inhib-
itors, currently used in patients with depression and
neurodegenerative disorders and devoid of well known
MAO inhibitor side effects, opens a possibility for the
compounds to be considered as candidate drugs for the
treatment of pathologies such as cardiovascular diseases
or prostate cancer (Fig. 6).
B. Inhibition of ROS Toxification
1. Myeloperoxidase Inhibitors. MPO contributes to
many chronic inflammatory syndromes and aims to
help treat, prevent, or at least stop the development of
these diseases in high-risk patients (Malle et al., 2007;
Lazarevic-Pasti et al., 2015). According to the mecha-
nism of inhibition, MPO inhibitors are divided into two
main categories: 1) reversible inhibitors and 2) irrevers-
ible inhibitors (Soubhye et al., 2016).
a. Reversible inhibitors. Dietary flavonoids are
useful for suppressing the lipid peroxidation of low-
density lipoprotein occurring by MPO/nitrite or per-
oxynitrite (Schewe and Sies, 2005) and protecting the
endothelial cell (Tian et al., 2017). Oral administra-
tion of (2)-epigallocatechin-3-gallate has been found
to prevent colitis in mice and to be essential for
mucoprotective effects (Nastase et al., 2016). Besides
flavonoids, other natural compounds showed good
activity against MPO, including ursolic acid, eugenol
(Narasimhulu and Vardhan, 2015), and harmaline
(Bensalem et al., 2014). Random and rational screen-
ing of non–anti-inflammatory drugs revealed that
metoclopramide, hydralazine (Soubhye et al., 2017),
and paroxetine (Soubhye et al., 2014) are potent MPO
inhibitors. In vivo experiments have disclosed that
different tryptamine compounds have an extensive
therapeutic index as promising candidates for anti-
inflammation. Use of N-acetyl lysyltyrosylcysteine
amide (KYC) in mice with experimental autoimmune
encephalomyelitis and middle cerebral artery occlu-
sion can reduce the migration of myeloid cells. This
inhibitor may be effective in the treatment of middle
cerebral artery occlusion, reduce the formation of
ClTyr and NO2Tyr, and consequently be useful for
treating brain damage after stroke (Yu et al., 2016). In
apolipoprotein E knockout mice that were given
a high-fat diet, ferulic acid (INV-315) showed a re-
duction of atherogenic plaques and improvement of
endothelial function, suggesting that the inhibition of
MPO could be useful for treating atherosclerosis (Liu
et al., 2012). None of these compounds have, however,
been translated to the clinics so far.
b. Irreversible inhibitors. Although this is a niche
mechanism, two of the major global players in the
pharmaceutical industry, i.e., AstraZeneca and Pfizer,
have embarked on the pharmacological development of
these compounds. However, the efforts have never gained
breadth. At least two candidates have been discontinued,
and progress on the single remaining one stays slow. Only
one compound, 4-aminobenzoic acid hydrazide, showed
in vivo decreased development of aortic atherosclerosis
(Békési et al., 2005) myeloid inflammation, tissue dam-
age in experimental autoimmune encephalomyelitis,
demyelinating diseases such as multiple sclerosis (MS)
Fig. 6. Clinical perspective of monoamine oxidase inhibitors. MAO-A and MAO-B catalyze the oxidative deamination of endogenous and exogenous
amines including several neurotransmitters, i.e., serotonin, norepinephrine, and dopamine, leading to H2O2 and aldehyde production. Dysregulation of
MAOs under certain pathologic conditions results in MAO activity and, therefore, elevated availability of MAO subproducts, i.e., H2O2. MAO inhibitors
are shown based on their current status, i.e., already marketed or under clinical development.
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(Forghani et al., 2012), blood-brain barrier dysfunction
(Üllen et al., 2013), and improved neurogenesis after
ischemic stroke (Kim et al., 2016). AstraZeneca had
advanced AZD3241 into phase II trials for Parkinson
disease (NCT01527695, NCT01603069) and multiple
system atrophy (NCT02388295; negative outcome). After
discontinuing development in April 2017, the company
released it for third-party development as a part of its
Open Innovation initiative. AZD3241 has been replaced
by AZD4831, which is in active development for heart
failure with preserved ejection fraction (HFpEF). A phase
I study (NCT03136991) in healthy males has been
completed; the second one, in patients with HFpEF, is
scheduled for completion at the end of 2020 (Table 2).
Pfizer’s thiouracil derivativePF-06282999, an irreversible
MPO inhibitor, entered clinical development for the
treatment of acute coronary syndrome in June 2012.
Pfizer announced its discontinuation in August 2017.
Deduced from the most recent patenting activity, Bristol
MyersSquibbCo. is now investingheavily in thediscovery
ofMPO inhibitors (Fig. 7). The company has international
patent applications for macrocyclic molecules (WO/2018/
005336) and a broad range of triazolopyridines and
triazolopyrimidines [WO/2017/160632, WO/2017/161145,
WO/2017/040451, WO/2017/040450, WO/2017/04044,
WO/2016/040419,WO/2016/040417 (Duclos et al., 2017)].
V. Targeting ROS Beyond Oxidases
A. Direct Antioxidants
Antioxidants have been used as nutraceuticals for the
prevention of aging and disease or even as a therapeutic,
often with little or no clinical control. The origin of the
antioxidant therapy concept is tightly connected to the
free radical theory of aging established by Harman
(1956, 1972), which was later expanded to also include
age-related diseases. According to this concept, free
radicals, i.e., any molecular species capable of indepen-
dent existence that contains an unpaired electron in an
atomic orbital, are generated from several sources,
including mitochondria, and cause progressive oxidant
damage to macromolecules, such as DNA, that limit cell
functionality. Consequently, antioxidants that reduce
free radical reactions should protect against aging and
disease. However, the existence of the large enzyme
family of NADPH oxidases and DUOXs with the sole
physiologic function to generate ROS clearly indicated
that ROS have at least two qualities, and thus, anti-
oxidants should be a double-edged sword.
In clinical trials, antioxidants have failed consistently to
show benefits in humans (Alpha-Tocopherol, Beta Caro-
tene Cancer Prevention Study Group, 1994; Marchioli,
1999; de Gaetano, 2001; Collins et al., 2002). Vitamin E
has been studied in the context of cardiovascular disease
in the CHAOS (Stephens et al., 1996) and HOPE (Hegele,
2000; Lonn et al., 2005) trials, inwhich it failed to improve
cardiovascular mortality. Moreover, several meta-
analyses focusing on the effect of vitamin E in CVD
showed similar results, i.e., no clear evidence of a positive
effect on either mortality or morbidity (Vivekananthan
et al., 2003; Eidelman et al., 2004; Kris-Etherton et al.,
2004; Shekelle et al., 2004). Similarly, no effect was
detected in cancer (Bjelakovic et al., 2004) or other causes
of mortality and quality of life (Bjelakovic et al., 2007).
Fig. 7. Role of myeloperoxidase in physiology and disease. MPO generates through H2O2 several reactive chlorinating (Cl2), bromating (Br2), and
radical (SCN2 NO2) species, which are later transformed into more reactive hypohalous acids [hypobromous acid (HOBr), hypothiocyanous acid
(HOSCN), hypochlorous acid (HOCl)] and reactive nitric species (NO•/ONNO2). Thus, MPO actively contributes to nucleoside and lipid oxidation,
together with protein (Tyr) nitration (NO2Tyr) and chlorination (ClTyr). Dysregulation of MPO results in a broad oxidative environment that
contributes to several pathologic conditions. MPO inhibitors are shown based on their current status, i.e., already marketed, under clinical testing, or
under preclinical development. 8-oxoG, 8-oxo-guanosine.
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N-acetylcysteine, which increases glutathione levels,
and vitamin E promote the acceleration of tumor pro-
gression by reducing p53 expression in rodents. Simi-
larly, supplements of vitamin E showed the same effect
on p53 levels. Indeed, high doses of antioxidants in
patients with diabetes were detrimental because of an
indirect increase in blood glucose levels (Sarangarajan
et al., 2017). Moreover, long-term supplementation also
provides a risk for metabolic syndrome incidence.
Vitamin E supplementation significantly increases
prostate cancer risk and even provides evidence of
increased hemorrhagic stroke risk. Moreover, chronic
use of multivitamins without clinical control, especially
lipid-soluble antioxidants at dosages above the upper
safety limit, has been associated with increased health
risks (Bjelakovic and Gluud, 2007). Moreover, during
the past years, teratogenic effects were reported and
associated with high intakes of vitamin A together with
accelerated bone loss and risk of fracture due to in-
creased osteoporosis.
Regarding vitamin C, epidemiologic studies initially
suggested that low plasma levels correlate with in-
creased inflammation and endothelial dysfunction
(Wannamethee et al., 2006). In the EPIC study, a vita-
min C–rich diet improved endothelium-dependent va-
sodilation and hemostasis (Sargeant et al., 2001). A
later meta-analysis, however, failed to show benefit in
reducing major cardiovascular events (Myung et al.,
2013). Specific meta-analyses claimed a beneficial effect
of vitamin C in breast cancer (Harris et al., 2014).
Ultra–high-dose therapy with vitamin C may be benefi-
cial in cancer through a pro- rather than an antioxidant
effect. In colon cancer, the effects of vitamin C have been
attributed to its oxidized form, dihydroascorbate (Chen
et al., 2008; Yun et al., 2015). In either non–small-cell
lung cancer or glioblastoma, the safety, not the efficacy,
of high-dose vitamin C injections was tested (Schoenfeld
et al., 2017). Vitamin Cmay help to alleviate some of the
side effects of antitumor treatment (Carr et al., 2014), but
conversely, other clinical trials had to be stopped because
of severe side effects by vitamin C (Subbarayan et al.,
2007). Thus, vitamin C fails to reduce all-cause mortal-
ity, and antioxidants do not exhibit beneficial effects in
either cardiovascular or other diseases (Bjelakovic et al.,
2012), whereas the antitumor, pro-oxidant effect of high-
dose vitamin C dihydroascorbate is to some degree open,
but far away from being recommended. Vitamin C has
also been suggested to increase the risk of calcium
oxalate kidney stones.
Coenzyme Q has been used in several trials with little
or no benefit. Recently, the 2CARE study was conducted
in a large cohort of patients with early Huntington
disease. This study was stopped for futility, as it would
be very unlikely (less than a 5% statistical probability)
to see a benefit of coenzyme Q10 treatment over placebo
(McGarry et al., 2017). Dietary polyphenols have also
been tested, leading to another translational failure
when positive data in animal models could not be
replicated in humans (McDougall et al., 2005; Yang
et al., 2011).
Some synthetic antioxidants also provided disap-
pointing results. The spin-trapping synthetic antioxi-
dant NXY-059 was used in two trials of patients with
ischemic stroke (SAINTI and SAINTII). NXY-059
showed no effect on mortality and neurologic function
(Lees et al., 2006; Shuaib et al., 2007). Several hypoth-
eses have been proposed to explain the failure of most
antioxidants in clinic practice, although the overall
reason is still unknown:
1. Broadly interfering with ROS biology, which will
inevitably also scavenge essential and physio-
logic ROS, is of general concern.
2. The concept that low ROS is beneficial or neutral
and that high ROS is always detrimental is not
sustainable.
3. There is no whole-body redox status, and even at
a cellular level, there are independent compart-
ments of ROS biology.
4. The molecular targets of the antioxidants are
usually poorly defined, leading to a broad mech-
anism of action mainly focused on ROS scaveng-
ing with neither specific subcellular localization
nor predefined enzymatic target (Cochemé and
Murphy, 2010).
5. Absorption, distribution, metabolism, excretion,
and bioavailability, i.e., pharmacokinetics and
pharmacodynamics of specific antioxidants, may
not have been analyzed sufficiently, and dosing
may have been wrong or insufficient (Manach
et al., 2005).
6. Inadequate trial duration may have resulted in
the underestimation of any therapeutic effect.
Chronic clinical trials might not last long enough
to obtain positive outcomes, and post-trial follow-
up may have had time and funding limitations
(Steinhubl, 2008).
Nevertheless, most antioxidant therapies not only
seem to be ineffective based on clinical evidence but are
also associated with some risk of detrimental outcomes
depending on the dose or pathology being treated
(Salehi et al., 2018).
One exception to the above may be edaravone (3-
methyl-l-phenyl-pyrazolin-5-one, MCI-186), which has
been approved for stroke (Miyaji et al., 2015) and/or
amyotrophic lateral sclerosis in some countries, includ-
ing Japan (Radicut) and the United States (Radicava),
but the market authorization application was with-
drawn in Europe. Edaravone is considered to act as
a free radical scavenger with neuroprotective effects
both in in vitro and in vivo models of ROS-related
neurodegenerative diseases, especially brain ischemia
(Lei et al., 2014; Sun et al., 2015) and ALS (Xu et al.,
2017). ROS have been considered as a critical player in
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ALS pathophysiology being involved in neuromotor
degeneration and glial and endothelial dysfunctions.
Indeed, edaravone, prevents motor neuron death
(Nagase et al., 2016). Preclinical studies hypothesized
that the neuroprotective effect of edaravone is medi-
ated by plasma membrane stabilization (Wu et al.,
2014b) via 1) scavenging hydroxyl radicals, 2) inhibit-
ing lipid peroxidation, and 3) playing a potent anti-
oxidant effect (Feng et al., 2011). Despite the recent
approval for ALS treatment, there are still limita-
tions, since the intravenous infusion is inconvenient
for the patients and costly (Hardiman and van den
Berg, 2017). Based on promising in vivo studies (Wu
et al., 2014b), multiple clinical trials were conducted
demonstrating an effect of edaravone in patients
diagnosed with stroke (Otomo et al., 2003) and
patients with acute cerebral large-vessel occlusion
as a subanalysis of the RESCUE-Japan Registry
(Miyaji et al., 2015). Several systematic reviews,
however, found no evidence for edaravone’s efficacy
(Lapchak, 2010), along with serious shortcomings in
clinical trial design, randomization, patient numbers,
inclusion and exclusion criteria, and outcome param-
eters (Feng et al., 2011). Edaravone has also been
investigated in a pilot for the treatment of acute
myocardial infarction (NCT00265239), ischemia-
reperfusion injury in patients with kidney transplan-
tation (NCT02644915), Parkinson disease, Alzheimer
disease, atherosclerosis, retinal diseases, and diabe-
tes mellitus. No clinical outcome data have been
released (Ahmadinejad et al., 2017).
B. Indirect Antioxidants: NRF2 Activators
Considering the failure of most direct antioxidants
in clinical studies, a new approach has been suggested
focused on the activation of the endogenous redox
homeostatic system. The advantage of this strategy is
to achieve redox regulation in the tissues, cells, or
organelles where it is required. Transcription factor
nuclear factor (erythroid-derived 2)-like 2, the master
regulator of the antioxidant response, is a very prom-
ising target, since it can be activated pharmacologi-
cally. NRF2 is a basic leucine zipper transcription
factor that forms heterodimers and controls the basal
and stress-inducible expression of over 250 genes
through its binding to the enhancer antioxidant re-
sponse element (Cuadrado et al., 2018, 2019). The
most successful NRF2 activators are electrophile
drugs that alter the structure of KEAP1 through the
interaction with several redox-sensitive cysteines,
including C151, C273, and C288. At least 30 recent
patents for NRF2 modulators are indexed in the
World Intellectual Property Organization. Although
most of these compounds proved to be useful to some
degree in preclinical proof-of-concept studies, only
a few have entered clinical trials approved, and even
fewer have reached phases II/III. The three most
successful examples are sulforaphane, synthetic tri-
terpenoids, and dimethyl fumarate. Sulforaphane is
an isothiocyanate obtained from cruciferous plants,
and it is already used so far in at least 32 clinical
studies of chronic diseases with an oxidant and
inflammatory component, including cancer, asthma,
chronic kidney disease, type 2 diabetes, and cystic
fibrosis (Houghton et al., 2013). In these studies,
sulforaphane improved blood glucose, lipid profile,
and molecular markers of ROS. Evgen Pharma Inc.
has developed a new cyclodextrin complex formula-
tion (Sulforadex) to increase its solubility and stabil-
ity. Nowadays, this compound is under phase II
clinical trial for the treatment of metastatic breast
neoplasm and subarachnoid hemorrhage. Synthetic
triterpenoids, derived from 2-cyano-3,12-dioxooleana-
1,9(11)dien-28-oate, are the most potent activators
of NRF2 and have been developed as antioxidant
modulators of inflammation (Dinkova-Kostova et al.,
2010). Despite excellent results in preclinical models,
serious concerns were raised in the first clinical trial
for diabetic nephropathy. Despite excellent results in
preclinical models, serious concerns were raised in
the first clinical trial for diabetic nephropathy since
the therapeutic effects were not related to NRF2, but
most likely to an off-target alteration of endothelin
signaling (Chen et al., 2015). Reata Pharmaceuticals
has developed a second generation of synthetic ole-
anane triterpenoid (RTA408). This compound is cur-
rently in phase II/III trials of patients with Friedreich
ataxia, mitochondrial myopathies, immunooncology,
and prevention of corneal endothelial cell loss after
cataract surgery. The best therapeutic results for an
NRF2 activator have been obtained so far with di-
methyl fumarate (DMF), which is the only NRF2
activator that has been approved as a drug by the
Food and Drug Administration and European Medi-
cines Agency. Initially used for the treatment of
psoriasis (Fumaderm), DMF is currently used as the
first-line oral therapy for MS (Tedfidera) (Bomprezzi,
2015). NRF2 activation by DMF correlates with de-
creased levels of proinflammatory markers and mac-
rophage infiltration in the spinal cord (Schimrigk
et al., 2006), which is in line with phase II/III trials
in which a significant reduction of MS lesions and
annualized relapse was demonstrated (Fox et al., 2012)
(Fig. 8; Table 3). However, uncontrolled Nrf2 activa-
tion can lead to deleterious effects due to the so-called
reductive stress event, which is detrimental in muscle
disorders and different cardiomyopathies (Pérez-
Torres et al., 2017; Bellezza et al., 2018). A novel
strategy for NRF2 activation is based on the develop-
ment of PPI inhibitors. These small molecules inter-
fere with the docking of NRF2 to KEAP1, hence
preventing NRF2 degradation. Several NRF2/KEAP1
PPI inhibitors have been developed and are under
patent protection, but further research is required to
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demonstrate that they are highly selective and that off-
target effects are negligible (Cuadrado et al., 2019).
C. Functional Repair of ROS-Induced Damage
All of the above approaches are aimed at reducing ROS
levels, either by reducing their synthesis or toxification or
by scavenging them. Functionally repairing ROS-induced
damage is, however, in our view, a promising complemen-
tary strategy that is consistent with the identified ROS
disease modules and, importantly, has already entered
clinical trialing and practice.
1. sGC Activators. Physiologically, soluble guany-
late cyclase mediates the generation of the second
messenger cGMP upon stimulation by NO. NO-cGMP
Fig. 8. Clinical pharmacology of NRF2. The KEAP1 E3 ligase adapter is a homodimer that presents NRF2 to the cullin3 (CUL3)/RING-box protein
(RBX) complex for ubiquitination and further proteasome degradation. This process restrains NRF2 protein levels. ROS (H2O2) and electrophiles alter
KEAP1 and lead to a stalled KEAP1/NRF2/CUL3/RBX complex. Then, newly synthetized NRF2 accumulates in the nucleus, makes heterodimers with
small transcription factor MAF (MAF) proteins, and activates target genes that contain the antioxidant response element (ARE). Clinically relevant
electrophiles, such as sulforaphane, dimethyl fumarate, bardoxolone, or omaveloxone, disrupt the capacity of KEAP1 to target NRF2 for degradation
and therefore increase NRF2 levels.
TABLE 3
Targeting ROS beyond oxidases: translation to the clinics
Target Drug Class Compound Name Pathology Clinical Trial Identifier CurrentStatus
Nrf2-
Keap1






Schizophrenia NCT02810964 Phase II
Lung cancer NCT03232138 Phase II
Autism NCT02677051 Phase II
Bladder cancer NCT03517995 Phase II
Clinical high-risk syndrome of psychosis NCT03932136 Phase III
Subarachnoid hemorrhage NCT02614742 Phase II
Bardoxolone (RTA402,
CDDO-me)
Chronic kidney diseases NCT03749447 Phase III
Pulmonary hypertension NCT03068130 Phase III
Autosomal dominant polycystic kidney NCT03918447 Phase III
Omaveloxolone (RTA 408) Friedreich ataxia NCT02255435 Phase II
DMF (approved) Multiple sclerosis — —
sGC sGC activator Cinaciguat Heart failure Terminated Terminated
HMR1766 Aortic valve stenosis NCT02481258 Phase II





Pulmonary hypertension — —
Vericiguat Chronic heart failure with preserved
ejection fraction
NCT02861534 Phase III
IW-1701 Sickle cell disease NCT03285178 Phase II
Achalasia NCT02931565 Phase II
Nelociguat (BAY60-4552) Male erectile dysfunction NCT01168817 Phase II
CDDO, 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate.
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signaling regulates several physiologic mechanisms,
including vasodilation, prevention of fibrosis, antith-
rombosis, anti-inflammation, and memory formation
(Ding et al., 2004; Dasgupta et al., 2015). The effects of
cGMP are mediated by a family of cGMP-dependent
protein kinases (PKG) (Francis et al., 2010). In addition
to its activation by cGMP, PKG has also been reported
to be activated by oxidative modification, presumably
by hydrogen peroxide, which can lead to vasorelaxation
(Burgoyne et al., 2007) and angiogenesis (Burgoyne
et al., 2015). Thus, ROS formation, on the one hand,
interferes with endothelium-dependent relaxation (pos-
sibly via superoxide scavenging of NO) and, on the other
hand, should induce vasorelaxation (by hydrogen per-
oxide acting as an endothelial hyperpolarizing factor).
What is unclear is whether these apparently contradic-
tory scenarios can coexist and what their pathophysio-
logical or therapeutic relevance is.
Nonphysiologic ROS production can affect the NO-
sGC-cGMP by direct chemical scavenging, resulting in
redox state changes of the NO responder soluble
guanylate cyclase or even, finally, in loss of its heme
group. The nonactive resulting enzyme, called apo-sGC,
is unable to respond to NO signaling, dramatically
reducing the bioavailability of cGMP (Casas et al.,
2015). The so-called sGC activators could functionally
reverse this mechanism. These compounds bind to both
the oxidase and heme-free forms of the enzyme, reac-
tivating it as the common NO-stimulated sGC and
preventing its proteasomal degradation (Meurer et al.,
2009). sGC activations can replace the weakly bound
oxidized heme in apo-sGC or also occupy the empty
heme pocket after the loss of the heme group (Stasch
et al., 2006), stabilizing the heme-free enzyme and
preventing degradation (Dasgupta et al., 2015). The
NO-sGC-cGMP signaling pathway is widely established
as a potent cardiovascular target because of its role in
hypertension and cardiovascular diseases. Therefore,
sGC activators have been preclinically tested not only
for cardiac hypertrophy (Costell et al., 2012), heart
failure (Breitenstein et al., 2017), and ischemia-
reperfusion injury (Nossaman et al., 2012) but also in
other pathologies such as fibrosis (Sandner and Stasch,
2017) and diabetic nephropathy (Boustany-Kari et al.,
2016) and stroke (Langhauser et al., 2018). After pre-
clinical validation, some sGC activators have been
translated to the clinical stage. Phase II clinical trials
were initiated recently using cinaciguat (BAY 58-2667),
which is a potent vasodilator (Dasgupta et al., 2015), as
a treatment of acute heart failure (NCT01067859,
NCT00559650) and heart decompensation (NCT01064037).
Unfortunately, all trials for decompensated heart failure
(COMPOSE 1, COMPOSE 2, and COMPOSE EARLY)
were terminated because of systemic hypotension and
difficulty enrolling patients. Another phase II clinical trial
using a new sGC activator, ataciguat (HMR 1766), as
a treatment of aortic valve calcification (NCT02481258)
was completed in July 2018, with no results available so
far (Fig. 4). Other indications, like neuropathic pain, have
also been investigated (NCT00799656) in a phase II trial
(Table 3).
2. sGC Stimulators. sGC stimulators can directly
activate sGC, resulting in an increase of cGMP forma-
tion in pathologic conditions and preventing NO-
dependent disorders (Nossaman et al., 2012). sGC
stimulators bind to an allosteric binding site of Fe(II)
heme-containing sGC, resulting in an NO-independent
sGC stimulation. Therefore, contrary to sGC activators,
stimulators do not work under the heme-free/oxidized
form of sGC (Dao et al., 2015). Different sGC stimula-
tors, i.e., BAY 41-8543 and BAY 41-2272, have been
preclinically tested in animal models of pulmonary
hypertension and show a decrease in systemic and
pulmonary arterial pressure, which has been translated
to the clinics (Nossaman et al., 2012). The clinical
success of Bayer’s riociguat (Adempas) in pulmonary
arterial hypertension prompted development efforts for
repurposing sGC stimulators to other therapeutic indi-
cations, although their biologic effects are less directly
related to ROS generation compared with the oxidases
(Sandner et al., 2019). Leading these efforts is the
collaboration between Merck Sharp & Dohme and
Bayer, which are conducting Vericiguat Global Study
in Subjects With Heart Failure With Reduced Ejection
Fraction (VICTORIA) (NCT02861534), a large phase III
clinical trial with vericiguat (BAY1021189/MK-1242-
001) (Follmann et al., 2017) in over 4800 patients with
HFpEF. It is scheduled for completion in 2019. When
VICTORIA was announced in 2016, it was considered
a surprise because vericiguat had produced a mixed
performance in the preceding phase II SOCRATES-
REDUCED trial. In fact, the candidate had failed to
meet its primary endpoint of achieving a significant
reduction in the biomarker N-terminal pro–B-type
natriuretic peptide, although a subgroup given the
highest dose, 10 mg, did show a benefit compared with
placebo. SOCRATES-PRESERVED (NCT01951638),
an earlier phase II trial in heart failure with preserved
ejection fraction, is being followed up with VITALITY-
HFpEF (NCT03547583), another phase II trial that is
supposed to be completed in November 2019. An sGC
stimulator would represent a promising mechanistic
deviation from the current small-molecule therapeutic
strategies for heart failure and could be especially
important in HFpEF. However, development might be
risky. Bayer has already discontinued cinaciguat (BAY
58-2667) for this indication. Indeed, Bayer has investi-
gated combinations of its approved phosphodiesterase
inhibitor vardenafil with nelociguat (desmethyl rioci-
guat, BAY60-4552; WO/2003/095451) in phase II clinical
trials for male erectile dysfunction. Highly interesting
is Ironwood Pharmaceuticals’ olinciguat (IW-1701), an
sGC stimulator in development for sickle cell disease.
STRONG SCD (NCT03285178) is a phase II trial that
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investigates disease-specific symptoms and pharmaco-
dynamic biomarkers over a 12-week treatment course; it
is planned for completion in July 2019 (Fig. 4). Olinciguat
is also in phase II for the esophageal sphincter disorder
achalasia (Table 3).
VI. Biomarkers of ROS
Current drug therapy is imprecise (Schork, 2015),
and since the 1950s, drug development has an ever-
increasing risk to fail (Scannell et al., 2012). Even the
most widely sold drugs in the United States only
provide relative benefit in one in four patients treated.
The number needed to treat (number of patients who
would need to be treated with one specific drug to
prevent one adverse outcome) remains extremely high
in more than 90% of approved drugs (Schork, 2015). To
move from here to precision medicine, patients need to
be stratified based on the fact that they will respond
with a high likelihood to a drug. Biomarker-based
stratification of patients in different populations may
help to target pharmacologically the different mecha-
nisms affected in each patient. The National Institutes
of Health Biomarkers Definitions Working Group de-
fined a biomarker as “a characteristic that is objectively
measured and evaluated as an indicator of normal
biological process, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention.”Moreover,
clinically relevant biomarkers must have diagnostic or
prognostic value or correlate with disease activity.
Finally, the stability, feasibility, and cost-effectiveness
are additional important criteria for clinical acceptance
of a biomarker. In the ROS field, a wide range of
biomarkers have already been tested, including in
humans. However, none has entered clinical practice
or any guideline.
A. Xanthine Oxidase and Myeloperoxidase
ROS-forming enzymes such as XO and MPO can be
found circulating in blood, independent of the release
mechanism. After administration of IFN or IFN inducers,
XO activity increases in tissues as well as in plasma
(Ghezzi et al., 1984). MPO is stored in granules of
neutrophils and monocytes and is released during de-
granulation (Zhang et al., 2001). Clinical studies have
previously used plasma or serum MPO levels as a poten-
tial prognostic biomarker of inflammation in cardiovas-
cular disease (Vita et al., 2004), myocardial infarction
(Cavusoglu et al., 2007; Khan et al., 2007), chronic
obstructive pulmonary disease (Morrow et al., 2015),
and cognitive impairment (Heringa et al., 2014). Another
alternative is to measure MPO activity. 3-Chlorotyrosine,
as well as chlorinated lipids, is a specific marker of MPO
action highly elevated in low-density lipoproteins (Hazen
and Heinecke, 1997). Several clinical studies have found
pronounced 3-chlorotyrosine levels in cardiovascular
(Cheng et al., 2008; Delporte et al., 2014) and rheumatoid
arthritis (Wu and Pizzo, 2001; Stamp et al., 2012) in
plasma or synovial fluid using high performance liquid
chromatography or liquid chromatography–mass spec-
trometry. To date, there is no specific and reliable anti-
ClTyr antibody available.
B. ROS-Dependent Protein Modification
Protein 3-nitrotyrosine (NO2Tyr), either within poly-
peptide sequences or as a free amino acid, is a marker of
nitrative stress. At least two mechanisms for its forma-
tion exist: 1) chemically, in a diffusion-limited reaction
between nitric oxide and superoxide and intermediate
peroxynitrite; and 2) enzymatically, by heme peroxi-
dases such asMPO or eosinophil peroxidase fromnitrite
and H2O2 (van der Vliet et al., 1997; Wu et al., 1999). In
inflammatory disease states, NO2Tyr has been identi-
fied as a stable marker of nitrative stress (Herce-Pagliai
et al., 1998). The analytical gold standard for NO2Tyr is
mass spectrometry (Tsikas and Duncan, 2014), but this
is not suitable for high-throughput analysis of clinical
samples. Other quantitative approaches, such as
ELISA (Pirro et al., 2007; Richardot et al., 2009), liquid
chromatography (Shishehbor et al., 2003; Misko et al.,
2013), or high performance liquid chromatography
(Kaur and Halliwell, 1994), are currently explored to
detect NO2Tyr clinically. However, extra effort is still
needed in the field to further use NO2Tyr as a clinical
biomarker, although the current data seem extremely
promising. Clinical studies have already explored the
potential of NO2Tyr as a marker of disease. It has been
reported that NO2Tyr can estimate cerebrovascular
stress after reperfusion in patients diagnosed with
stroke (Bas et al., 2012). In addition, nitrated fibrinogen
has also been detected in patient samples after ischemic
stroke (Ill-Raga et al., 2015), and it has been suggested
to be a cardiovascular disease risk factor (Heffron et al.,
2009).
C. ROS-Dependent DNA/RNA Modification
DNA and RNA are also targets and biomarkers of
ROS oxidation, with 8-oxo-29-deoxyguanosine (8-oxodG)
and 8-oxo-guanosine being the most common oxidative
lesions, respectively. They are secreted into the urine
and can be measured, usually by chromatography
coupled with MS (Weimann et al., 2001). They provide
information about systemic ROS and are lacking in
high-ROS conditions in specific organs. Nevertheless,
8-oxodG and 8-oxo-guanosine are among the most
relevant ROS biomarkers examined. In fact, recent
systematic reviews and meta-analysis studies have
validated and highlighted the role of 8-oxodG as a bio-
marker in, e.g., cardiovascular disease (Di Minno et al.,
2016), chronic heart failure, and Parkinson disease (Wei
et al., 2018).
The field of ROS biomarkers is constantly growing,
and therefore, extensive wet laboratory validation
studies are still required. We have highlighted some of
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the most ROS-relevant biomarkers, with a focus on
stable oxidativemodifications.However, there are plenty
more worth mentioning—e.g., vasodilator-stimulated
phosphoprotein phosphorylation levels in platelets are
used in the clinic for drug monitoring. Although several
methods have been discussed, antibody-based methods
remain the most feasible in a point-of-care setting.
Moreover, if disease definitions will become pathway
modules, they need to be analyzed in cells or tissue. Since
most proteins are present in most cells, most pathways
may be assessable in circulating blood cells or platelets.
One potential addition to this are recent developments in
liquid biopsies and harvesting rare circulating cells such
as tumor cells (Luecke et al., 2015) or endothelial cells
(Farinacci et al., 2018).
VII. Summary
For decades, ROS have been proposed as a cause of
aging and numerous diseases, primarily because of
correlation with the detection of ROS or ROS bio-
markers. Antioxidant therapy to scavenge ROS sounded
like a logical intervention but failed for reasons that
we now understand. The new therapeutic approaches
reviewed here no longer focus on ROS but on classic
pharmacological protein targets, i.e., 1) ROS sources, 2)
ROS toxifiers, 3) activating the endogenous antioxidant
defense systems, and 4) functionally repairing ROS-
induced damage. They jointly represent the future of
redox medicine, a field distinct of and synergistic with
general ROS biology. Pathologic overexpression or over-
activation of specific enzymatic sources of ROS can be
selectively inhibited without affecting physiologic sour-
ces of ROS and physiologic signaling. With respect
to isoforms of NOX, NOS, MAO, XO, and MPO,
their inhibition has resulted in promising therapeutic
approaches currently under development in late clinical
stages, i.e., VAS203, in phase III for traumatic brain
injury, and GKT-831, in phase III for diabetic nephrop-
athy. XO and MAO inhibitors have been approved,
although with different mechanisms in mind, but their
clinical efficacy may still involve ROS aspects. In any
case, the latter opens new clinical opportunities through
repurposing strategies for mechanism-based ROS indi-
cations, e.g., XO inhibitors for congestive heart failure,
MAO inhibitors for macula detachment, or NOX inhib-
itors for stroke. Activation of endogenous antioxidant
defense systems such as the master redox regulator
NRF2 may represent a viable alternative to the futile
exogenous antioxidants, as NRF2 activators will phys-
iologically modulate ROS and have indeed provided
clinical success, e.g., in multiple sclerosis. These ROS-
centric approaches are complemented by functionally
repairing ROS-induced damage. The best example of this
is soluble guanylate stimulators in pulmonary hyperten-
sion (riociguat) and heart failure (vericiguat) that sensi-
tize sGC for lower NO levels to reach a physiologic cGMP
signal. sGC activators are able to functionally repair
damaged sGC in its apo-sGC state, e.g., for aortic valve
calcification (ataciguat). The redefinition of diseases by
causal molecular modules will lead to mechanism-based
combination therapies, i.e., network pharmacology, and
therapeutic synergy between many of the above drug
principles if they act in the same module. Finally,
mechanism-based validated biomarkers, once they be-
come available, will enable 1) mechanism-based rather
than phenotype-based patient stratification, 2) a higher
success rate of subsequent interventional clinical trials,
and 3) lower numbers needed to treat in clinical practice
for ROS-related diseases as a role model for precision
medicine.
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